Axol Bioscience Developed New Stem Cell Type for Treatment of Neurodegenerative Diseases

Axol Bioscience is launching a new line of Human induced Pluripotent Stem Cells (iPSC)-derived Microglia for the consistent and reproducible study of neuroglia and their involvement in neurodegenerative diseases, including Alzheimer’s disease, multiple sclerosis and Parkinson’s disease.

Cambridge/UK — Microglia are commonly described as the immune cells of the brain. Human iPSC-derived Microglia offer scientists the opportunity to integrate this clinically important cell type into their in vitro models and assays of neurogenesis and neurodegeneration. Axol generates physiologically relevant Human iPSC-derived Microglia from a single donor with a normal karyotype, providing a homogenous population that is assay-ready in just four days.

The variability associated with traditional microglia cell lines, together with limited availability, poses significant challenges for pharmaceutical and biotech companies developing novel therapeutics to treat neurodegenerative diseases. Yichen Shi, Chief Executive Officer, Axol Bioscience argues that the launch of Human iPSC-derived Microglia would provide scientists with a reproducible, physiologically relevant model in an easy-to-use, assay-ready format for investigating neuroglia involvement in neurodegeneration and neurodevelopment.

UK: New Elisa Assay

The Native Antigen Company Launched New Zika Immunoassays

29/11/2018 - The Native Antigen Company has launched a series of immunoassays for Zika virus, offering researchers in academia, public health and drug discovery the capability to work with high levels of specificity and sensitivity. Unlike previous methods, the new assays have little or no cross-reactivity with other flaviviruses, including Dengue, West Nile, Yellow Fever, Japanese Encephalitis, Tick-Borne Encephalitis and Usutu virus. read...

The homogenous and reproducible population of the Human iPSC-derived Microglia exhibits physiologically relevant functionality with highly phagocytic activity and secretion of cytokines in response to pathogens. Axol’s Human iPSC-derived Microglia also express the microglia-specific marker Transmembrane protein 119 (TMEM119) along with myeloid markers Triggering Receptor Expressed on Myeloid cells 2 (TREM2) and Ionised Calcium Binding Adaptor molecule-1 (IBA-1). The expression of these phenotypes means the Microglia provide a suitable model for investigating neuroinflammation in Alzheimer’s disease, multiple sclerosis and Parkinson’s disease.